https://www.thebodypro.com/category/hiv-treatments-in-development
HIV Treatment Strategies

HIV Treatments in Development

The Latest

HIV Remission: The Quest to Turn Lessons From Exceptional Cases Into Solutions Img

HIV Remission: The Quest to Turn Lessons From Exceptional Cases Into Solutions

Researchers are attempting to establish how to make long-term HIV remission possible after finding that HIV can be suppressed naturally in some people for a long time after they have been on a short spell of treatment.

Long-Acting Drugs for HIV Img

Long-Acting Drugs for HIV

An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.

One on One With Sharon Lewin Img
Viewpoints

One on One With Sharon Lewin

The noted HIV researcher reflects on recent advances, the search for a cure, and the long road ahead.

Bictegravir vs. Dolutegravir Img
News

Bictegravir vs. Dolutegravir

Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.

Lab Chat: An Interview With Dr. Shomyseh Sanjabi Img
Viewpoints

Lab Chat: An Interview With Dr. Shomyseh Sanjabi

Sanjabi talks about her early interest in science, her innovative research toward an HIV cure, and the importance of mentoring early career investigators.

Estimating the Total Size of the HIV Reservoir Img

Estimating the Total Size of the HIV Reservoir

Researchers estimated a total body burden of as many as seven million cells expressing HIV RNA at any given time in tissues, despite viral load suppression to undetectable levels in the blood.

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies Img
Conference Coverage

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies

Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.

Signal That ABX464 Reduces Viral Reservoir but Not Time to Viral Rebound After Treatment Interruption Img
Conference Coverage

Signal That ABX464 Reduces Viral Reservoir but Not Time to Viral Rebound After Treatment Interruption

New data presented at EACS 2017 suggested that the investigational REV inhibitor ABX464 might reduce the HIV viral reservoir in a study that included a treatment interruption.

An Overview of Cabotegravir Img

An Overview of Cabotegravir

Other Names: 744 LA, CAB, GSK-1265744, GSK1265744, GSK744, GSK744 LA, GSK744 LAP, S-265744, S/GSK1265744, cabotegravir LA, cabotegravir sodium Drug Class: Integrase Inhibitors Molecular Formula: C19 H17 F2 N3 O5 Registry Number: 1051375-10-0 (CAS) Ch...

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017 Img
IDWeek

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.